Trial reportJournal of clinical laboratory analysis1998
A sandwich enzyme immunoassay for measuring AD7C-NTP as an Alzheimer's disease marker: AD7C test.
Trial report in Journal of clinical laboratory analysis, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 33 citations in OpenAlex.
- Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of alzheimer's disease.Journal of nanobiotechnology · 2021Review
- Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.Journal of molecular neuroscience : MN · 2014Review
- A literature review of AD7c-ntp as a biomarker for Alzheimer's disease.Annals of Indian Academy of Neurology · 2013Review
- Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration.Alcohol (Fayetteville, N.Y.) · 2009Article
- Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.Molecular diagnosis & therapy · 2008Review
- Alzheimer's disease and mild cognitive impairment.Neurologic clinics · 2007Review
- Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease.BMC neurology · 2007Article
- Cerebrospinal fluid protein biomarkers for Alzheimer's disease.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2004Review
- Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker.Journal of clinical laboratory analysis · 1998Article
- Urinary AD7c-NTP Evaluates Cognition Impairment and Differentially Diagnoses AD and MCI.American journal of Alzheimer's disease and other dementiasArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A simple, fast, reliable, and specific immunoassay has been developed to detect and measure AD7C-NTP, a biochemical marker for Alzheimer's disease, in cerebrospinal fluid (CSF). This assay, called the AD7C Test, is an enzyme-linked sandwich immunoassay (ELSIA) using 96 well microtiter plates. The plate surface is coated with a monoclonal antibody (N3I4) which has a high affinity and specificity for AD7C-NTP, capturing it effectively from CSF samples. The detection was achieved using a polyclonal antibody (ADRI). Both N3I4 and ADRI were generated using recombinantly produced AD7C-NTP. The assay is highly sensitive (30-50 pg), linear to 2.0 ng (r2 > 0.99), and reproducible (C.V. < 10%). The utility of the assay has been demonstrated using CSF specimens from early Alzheimer's disease patients and age matched controls (sensitivity of 89% and specificity of 89%).
Indexed as
Identifiers
9671174PMC6807901W2008075718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.